Rigorous Detection of Nitrosamine Contaminants in Metformin Products: Balancing Product Safety and Product Accessibility
Nitrosamines are a class of chemicals that commonly occur as impurities in water, beverages, and foods (particularly in cured and grilled meats). Although nitrosamines are generally regarded to be carcinogenic, small amounts of exposure are not considered to be harmful. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 12, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Effect of Metformin Across Renal Function States in Diabetes Effect of Metformin Across Renal Function States in Diabetes
Metformin lowered cardiovascular and renal risk in patients with type 2 diabetes across distinct renal function states, including patients considered contraindicated.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 5, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

Is Metformin a'Drug for All Diseases'? Is Metformin a'Drug for All Diseases'?
Metformin, a staple of glucose management for decades, is now being studied for use in a wide range of diseases from carotid atherosclerosis to vitiligo.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 27, 2024 Category: Drugs & Pharmacology Tags: Internal Medicine Source Type: news

Metformin Shows Potential to Prevent Neovascular AMD Metformin Shows Potential to Prevent Neovascular AMD
A case-control study of 174,000 individuals found that use of metformin was associated with a reduced odds of developing wet, age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2024 Category: Consumer Health News Tags: Ophthalmology Source Type: news

Metformin Added to Insulin Not Beneficial for T2D in Pregnancy
TUESDAY, Dec. 12, 2023 -- For pregnant women with type 2 diabetes, the addition of metformin to insulin does not affect composite adverse neonatal outcomes, according to a study published in the Dec. 12 issue of the Journal of the American Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2023 Category: Pharmaceuticals Source Type: news

Metformin for Diabetes in Pregnancy: Maybe Not, Trial Says
(MedPage Today) -- Adding metformin to insulin treatment for pregnant women with preexisting type 2 or gestational diabetes did not reduce composite neonatal adverse outcomes, according to the randomized MOMPOD trial. The composite outcome -... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 12, 2023 Category: Urology & Nephrology Source Type: news

Metformin Linked to Lower Odds of Developing AMD in Non-Diabetic Patients
(MedPage Today) -- Use of metformin was associated with lower odds of developing age-related macular degeneration (AMD) among patients without a diabetes diagnosis, offering more evidence of a possible role for the inexpensive drug in eye health... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 7, 2023 Category: Endocrinology Source Type: news

Why ‘ Healthspan ’ May Be More Important Than Lifespan
In 2014, then-57-year-old bioethicist Dr. Ezekiel Emanuel wrote an infamous essay titled, “Why I Hope to Die at 75” for The Atlantic. His argument boiled down to this: it’s not worth living as long as humanly possible if those efforts yield extra decades defined by disease and poor health, which data suggest is the fate awaiting many people in the U.S. Nearly a decade later, neither Emanuel’s mind nor the statistics have changed much. Emanuel still says he plans to stop most life-extending medical care once he reaches age 75, though he’s healthy enough that he expects to live longer natural...
Source: TIME: Health - November 30, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Source Type: news

SugarMDs LLC Issues Voluntary Nationwide Recall of Advanced Glucose Support Supplements Capsules Due to Presence of Undeclared Glyburide and Metformin
Maryland Heights, MO, SugarMDs, LLC is voluntarily recalling Lot: 22165-003 Advance Glucose Support Supplement in 60, 120 and 180 count bottles to the consumer level. FDA analysis has found the product to be tainted with glyburide and metformin. Glyburide and Metformin are active ingredients found (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 29, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK'd
(MedPage Today) -- The FDA announced a voluntary recall of an over-the-counter glucose support supplement for the presence of metformin and glyburide. Over the past two decades, the prevalence of diabetes and obesity, respectively, increased from... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 21, 2023 Category: Endocrinology Source Type: news

FDA Warns About Over-the-Counter Glucose-Lowering Product FDA Warns About Over-the-Counter Glucose-Lowering Product
Now-discontinued"Dr. Ergin ' s SugarMD Advanced Glucose Support" was found to contain glyburide and metformin, which are only available by prescription.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 7, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Should We End Obesity?
It’s unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to change not just U.S. medicine, but U.S. culture. Ozempic has done all three. Approved in 2017 as a type 2 diabetes medication, Ozempic has largely made its name—and a fortune for its manufacturer, Novo Nordisk—as a weight-loss aid. Novo Nordisk knew early on that diabetes patients often lost weight on the drug, but even company executives couldn’t have guessed how widely it would eventually take off as both ...
Source: TIME: Health - November 7, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs feature healthscienceclimate Magazine TIME 2030 Wellbeing Source Type: news

FDA Approves Zituvimet (sitagliptin and metformin hydrochloride) to Treat Adult Patients With Type 2 Diabetes Mellitus
November 06, 2023, Ahmedabad, India --  Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as " Zydus " ) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 6, 2023 Category: Drugs & Pharmacology Source Type: news

Can Diabetes Drugs Lower the Risk of Age-Related Dementia?
A new study suggests that stopping metformin speeds up cognitive decline in older people who have diabetes. What does this mean for them? (Source: WebMD Health)
Source: WebMD Health - November 6, 2023 Category: Consumer Health News Source Type: news

More Evidence Metformin May Be Neuroprotective More Evidence Metformin May Be Neuroprotective
Stopping metformin was linked to an increased risk for dementia diagnosis in a large cohort of adults with T2D, providing more evidence of the drug ’s potential neuroprotective effects.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 1, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news